ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A
暂无分享,去创建一个
J. Oldenburg | B. Konkle | K. Pasi | J. Mahlangu | B. Nolan | G. Young | K. Nogami | D. Rudin | Huixing Yuan | Nikola Tripković